يعرض 1,441 - 1,460 نتائج من 21,342 نتيجة بحث عن '(( significant decrease decrease ) OR ( significant reduction decrease ))', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1441

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  2. 1442

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  3. 1443

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  4. 1444

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  5. 1445

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  6. 1446

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  7. 1447

    Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula... حسب Lin Lin (46073)

    منشور في 2025
    "…P values were calculated via the two-sided Wilcoxon test. ns, not significant, **, P < 0.01 and ****, P < 0.0001. (G) Feature plot showing LDLR expression levels in C1Q+ macrophages between CAG and control samples.…"
  8. 1448
  9. 1449
  10. 1450
  11. 1451
  12. 1452
  13. 1453

    Data Sheet 1_Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation—patients with AF produce lower SN levels than healthy individuals: the SAFE r... حسب Jiří Plášek (21805048)

    منشور في 2025
    "…Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, p = 0.032). …"
  14. 1454

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... حسب Chanel Avenant (409756)

    منشور في 2025
    "…The substantial and differential decrease in testosterone and SHBG levels does not explain our previous finding of no detected decrease in risky sexual behavior or sexual function for DMPA-IM or NET-EN users from D0 to 25W. …"
  15. 1455

    Experimental data support. حسب Quan Shen (37564)

    منشور في 2025
    الموضوعات:
  16. 1456

    Compression index of improved red clay. حسب Quan Shen (37564)

    منشور في 2025
    الموضوعات:
  17. 1457

    Test specimen. حسب Quan Shen (37564)

    منشور في 2025
    الموضوعات:
  18. 1458
  19. 1459

    Particle size distribution curve. حسب Quan Shen (37564)

    منشور في 2025
    الموضوعات:
  20. 1460

    Compressibility modulus of improved red clay. حسب Quan Shen (37564)

    منشور في 2025
    الموضوعات: